ERT buys CRS adding respiratory diagnostics to offering

- Last updated on GMT

Related tags: Contract research organizations, Clinical research

Cardiac monitoring and ePRO specialist ERT has added respiratory diagnostics and device manufacturing services to its offering with the acquisition of CareFusion Research Services (CRS) for $81m (€61m).

CRS, which was spun off from Cardinal Health in 2007, also provides pharmaceutical companies and contract research organizations with cardiac safety monitoring and electronic patient reported outcomes (ePRO).

eResearch Technology (ERT) CEO Michael McKelvey said the acquisition will help “clients in the clinical research industry with the ability to more efficiently capture, process and distribute clinical data during all phases of drug development.”

In wider terms the deal may indicate that the wave of consolidation among contract research organizations (CRO), demonstrated most recently by Charles River Laboratories bid for Wuxi​, is starting to be mirrored by the ancillary research services industry.

Related news

Show more

Related products

show more

Laboratory Solutions for COVID-19 Clinical Trials

Laboratory Solutions for COVID-19 Clinical Trials

Q2 Solutions | 10-Jun-2020 | Clinical Study

As a leading laboratory services organization for trials across the globe, we are proud to partner with clients to support COVID-19 clinical trials. Our...

Parents as Gatekeepers for Children with Cancer

Parents as Gatekeepers for Children with Cancer

PRA Health Sciences | 08-Jun-2020 | Technical / White Paper

The RACE for Children Act will require new drugs intended for adult cancer treatment to also be studied in pediatric cancers when the molecular target...

RACE Act Prompts Pediatric Oncology Trials

RACE Act Prompts Pediatric Oncology Trials

PRA Health Sciences | 04-May-2020 | Technical / White Paper

Many providers prescribe drugs off-label to pediatric patients, even though there have been few pediatric trials for many of these drugs. In response,...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 01-Mar-2020 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

Related suppliers

Follow us

Products

View more

Webinars